Sam Brusco, Associate Editor05.06.24
GE HealthCare has revealed Signa Magnus, a U.S. Food and Drug Administration (FDA) 510(k)-pending, head-only MR scanner to explore advancements in neuroscience.
Previously, neuroscience has been restricted by performance limitations of whole-body MR systems. Technological and biological limitations have constrained neuroscience, particularly in the study of psychiatric diseases and neurological disorders like Alzheimer’s.
Signa Magnus is GE HealthCare’s most advanced 3T MR imaging device and is designed for neurological and oncological research for head-only imaging. It offers detail and clarity that allows in-depth exploration of brain microstructure, microvasculature, and function.
Gradient performance is powered by GE HealthCare’s HyperG technology, featuring 300 mT/m and 750 T/m/s to detect fine details that were previously unattainable. Researchers can use it to push the boundaries of advanced anatomical, diffusion and functional techniques, according to the company. This is amplified by GE HealthCare’s latest deep-learning algorithms.
Signa Magnus’ asymmetric gradient design boosts diffusion performance for extremely high B-value diffusion with short echo times (TEs). This further refines understanding of neural architecture. Many GE HealthCare 3.0T systems are also upgradable to Signa Magnus.
"With SIGNA MAGNUS, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care,” said Kelly Londy, CEO, MR GE HealthCare. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what's possible in MR imaging. The potential impact of SIGNA MAGNUS on patient outcomes and our understanding of the human brain is profound."
Previously, neuroscience has been restricted by performance limitations of whole-body MR systems. Technological and biological limitations have constrained neuroscience, particularly in the study of psychiatric diseases and neurological disorders like Alzheimer’s.
Signa Magnus is GE HealthCare’s most advanced 3T MR imaging device and is designed for neurological and oncological research for head-only imaging. It offers detail and clarity that allows in-depth exploration of brain microstructure, microvasculature, and function.
Gradient performance is powered by GE HealthCare’s HyperG technology, featuring 300 mT/m and 750 T/m/s to detect fine details that were previously unattainable. Researchers can use it to push the boundaries of advanced anatomical, diffusion and functional techniques, according to the company. This is amplified by GE HealthCare’s latest deep-learning algorithms.
Signa Magnus’ asymmetric gradient design boosts diffusion performance for extremely high B-value diffusion with short echo times (TEs). This further refines understanding of neural architecture. Many GE HealthCare 3.0T systems are also upgradable to Signa Magnus.
"With SIGNA MAGNUS, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care,” said Kelly Londy, CEO, MR GE HealthCare. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what's possible in MR imaging. The potential impact of SIGNA MAGNUS on patient outcomes and our understanding of the human brain is profound."